Overall survival (HR = 1.52, 95%CI = 0.91-2.55, P = 0.1532) and progression-free survival (HR = 1.22, 95%CI = 0.75-1.99, P = 0.4215) were similar in both groups. However, acute toxicities during RT period revealed a significant reduction of grade 3/4 vomiting (23% vs. 0%, P < 0.0001), mucositis (55% vs. 16%, P < 0.0001), and neck dermatitis (31% vs. 16%, P = 0.0041) in the NeoCT-RT group, resulting in fewer emergency room visits (10.2% vs. 1.6%, P = 0.0071). Severe treatment-related late toxicity (15% vs. 14%, P = 0.9590) and the occurrence of second malignancy (3.9% vs. 5.4%, P = 0.7887) also showed no differences. We concluded that NeoCT-RT could be an attractive alternative option of CCRT for advanced NPC.
Results
Patient characteristics, initial response, and patterns of failure. The consensus guidelines of the initial treatment for advanced NPC in our hospital were either CCRT (according to guidelines from the Western countries) or NeoCT-RT (by our past experiences) 7, 8 . This study enrolled 256 patients who received either CCRT (n = 127) or NeoCT-RT (n = 129) as their initial definitive treatment from December 2004 to January 2009. Table 1 outlines the pre-treatment characteristics of the patients. There were no statistically significant differences in terms of age, gender, performance status, pathologic type, T-classification, N-classification, or overall stage. However, patients who received NeoCT-RT had a higher pretreatment plasma EBV DNA levels (median, 962 copies/mL; interquantile range, 163-2381) than those who received CCRT (median, 444 copies/mL; interquantile range, 55-2335). The difference showed borderline significance (P = 0.076).
Tumor response, evaluated 2-3 months upon completion of RT revealed that NeoCT-RT showed better complete response rates than CCRT (96.1% vs. 85.0%, P = 0.0019).
Seventy-three of 127 (57.5%) patients in the CCRT group and 82 of 129 (63.6%) in the NeoCT-RT group possessed high-risk factors (P = 0.3853). After finished initial CCRT or NeoCT-RT, patients with high-risk factors agreed to receive post-RT adjuvant tegafur-uracil were no significant differences between the CCRT and NeoCT-RT subgroup (83.6% vs. 91.5%, P = 0.2106).
After a minimal follow-up time of 6 years for surviving patients, 26 .8% (34/127) and 23.3% (30/129) of patients who received CCRT and NeoCT-RT respectively, developed a tumor relapse (P = 0.6134). Table 2 demonstrates the detailed patterns of failure. There were no significant differences in local, regional, and distant failures (P = 0.6033, 1.0000, and 0.1809) between the two groups.
Survival outcome. The Acute toxicity and tolerance. Acute toxicities during the NeoCT period for the 129 patients who had enrolled in the NeoCT-RT group were well-tolerated and usually mild in their severity ( toxicity included leucopenia (9%), anemia (16%), thrombocytopenia (2%), vomiting (12%), and body weight loss (1%). There was no grade 3/4 mucositis exhibited. Ninety-five percent (122/129) patients were able to complete the scheduled 10 weekly NeoCT. Only 7 patients received less than 10 weekly dose of NeoCT (9 doses in 3 cases, 8 doses in 2 cases, and 7 doses in 2 cases) due to toxicities (n = 2), patient's refusal (n = 2), acute hepatitis (n = 2), and hyperglycemic hyperosmolar non-ketotic syndrome (n = 1). Ninety-eight percent (126/129) patients were able to receive weekly NeoCT on time, and only 3 patients had one-week delays due to toxicity. Table 4 compares acute toxicities during the IMRT phase between CCRT and NeoCT-RT. There were no significant differences in hematologic toxicities between the two groups. However, patients who received CCRT had a significantly higher incidence of grade 3/4 vomiting (23% vs. 0%, P < 0.0001), mucositis (55% vs. 16%, P < 0.0001), neck radiation dermatitis (31% vs. 16%, P = 0.0041), and weight loss (6% vs. 0%, P = 0.0068), than those who received NeoCT-RT. One patient in the CCRT refused further RT at 56 Gy. The remaining patients The accumulated acute toxicities during the whole treatment course of combined NeoCT and RT arm revealed similar results except for anemia compared with CCRT arm. There were significant less grade 3/4 mucositis (P < 0.0001), radiation dermatitis (P = 0.0025), vomiting (P = 0.0175), and weight loss (P = 0.0294) favoring NeoCT-RT arm. But CCRT arm had less grade 3/4 anemia occurrence (P = 0.0002).
Thirteen of 127 (10.2%) patients in the CCRT group were unable to complete the planned two cycles of concurrent chemotherapy due to toxicity (n = 5) and patient's refusal (n = 8). The second cycle concurrent chemotherapy needed to be delayed for more than one week in 5 of the patients.
Because the incidence and severity of mucositis and vomiting were higher throughout the CCRT group, these patients had a greater occurrence of elevated serum creatinine levels (23.6% vs. 1.6%, P < 0.0001), hyponatremia (8.7% vs. 0.8%, P = 0.0072), and more additional emergency room visits (10.2% vs. 1.6%, P = 0.0071), than those who were part of the NeoCT-RT group. Other severe events during IMRT included pneumonia in one patient (CCRT group) and hepatitis in 4 patients (1 in CCRT and 3 in the NeoCT-RT group). However, no toxicity resulting in fatalities occurred in either group.
Late Events. Severe late toxicities occurred in 15% (19/127) patients of the CCRT group and 14% (18/129) patients of the NeoCT-RT group (P = 0.9590). These included hearing impairment (6.3% vs. 4.7%, P = 0.7604), cranial nerve palsy (4.7% vs. 4.7%; P = 1.0000), neck fibrosis (3.1% vs. 3.9%, P = 1.0000), vessels damage (0.8% vs. 1.6%, P = 1.0000), and brachial plexus injury (0.8% vs. 0%, P = 1.0000). Second malignancies were noted after successful NPC treatment in 5 of 127 patients (2 lungs, 2 breasts, and 1 rectum) who received CCRT and in 7 of 129 patients (3 lungs, 2 tongues, 1 breast, and 1 lymphoma) who received NeoCT-RT. The incidence rates of the second primary were similar in both groups (3.9% vs. 5.4%, P = 0.7887).
Discussion
RT alone has long been proven to be inferior to combined chemoradiotherapy (CCRT + AdjCT, CCRT, NeoCT-RT) in locally advanced NPC 5, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . The Intergroup-0099 study was the first phase III randomized trial to show both OS and PFS benefits in the CCRT + AdjCT group for advanced NPC 5 . This treatment modality has become the most popularly used standard of care since 1998. Several large phase III randomized trials from endemic areas with a similar design confirmed the findings of the Intergroup study [10] [11] [12] [13] [14] . In addition, CCRT alone has also been accepted as another daily practice option with the support of phase III randomized trials 9, [15] [16] [17] [18] . Three older, randomized trials published more than 10 years ago also demonstrated that NeoCT-RT offered significant improvement in disease-free survival 19 or relapse-free survival [20] [21] [22] , and better, albeit non-significant improvement of OS than the use of RT alone. But no prior randomized studies compared the difference between NeoCT-RT versus CCRT.
Although , the Sun Yat-sen University Cancer Center, Guangzhou, China obtained better failure-free survival, overall survival, and distant failure-free survival than the CCRT alone 26 . However another two studies containing relatively small sample size (less than 200 patients) revealed that there were no significant differences in terms of PFS 23 or disease-free survival 24 between the NeoCT + CCRT and CCRT alone group. The Hong Kong NPC-0501 trial 25 recruited the largest sample size (n = 801). Unfortunately, no definite conclusions were drawn due to the design of multiple aims being incorporated into one trial exploring 1) chemotherapy sequence: induction vs. adjuvant, 2) chemotherapy regimen: oral capecitabine vs. intravenous 5-FU, and 3) RT schedules: hyperfractionated vs. conventional. The results of this retrospective study revealed that there were no significant differences in terms of various survivals between CCRT and NeoCT-RT.
After carefully re-visiting larger trials which were undertaken during the last ten years, we found that most previous trials had failed to demonstrate a significant improvement of OS in any combined chemoradiotherapy groups. We believe that OS could therefore be similar among the different combinations of initial chemoradiotherapy. Since designing a superior initial chemoradiotherapy regimen (CCRT, NeoCT-RT, or NeoCT-CCRT) to prolong OS would not easily be achieved, selecting a low-toxic regimen may be an option beneficial to the patients.
Although CCRT is the most effective initial treatment for locally advanced NPC, it has been shown to induce a significant increase of acute toxicities in all previous reports. NeoCT-CCRT is also an effective initial treatment modality. However, the acute toxicities displayed during CCRT after NeoCT were usually reported as being similarly severe or even worse than the use of CCRT alone. A recent retrospective study from the Sun Yat-sen University Cancer Center, Guangzhou, China found that the treatment outcomes of the NeoCT + RT and CCRT were similar. However, CCRT led to higher rates of acute and later toxicities for 214 patients with ascending-type NPC 27 . Results of this study confirmed the findings mentioned above with similar sample size (256 patients). In addition, we had a longer follow-up time (median 72.0 vs. 46.8 months) and more uniform dosage of NeoCT or ConCT than the above study. Several unique features of our NeoCT-RT design may have contributed to the significant reduction of acute toxicities when compared with CCRT. First, we used weekly P-FL, as opposed to the conventional tri-weekly PF or TPF during the NeoCT phase. Secondly, we used RT on its own, rather than CCRT after NeoCT, in order to avoid more side effects from CCRT. Thirdly, the dose intensity of our 10 weekly P-FL NeoCT was determined to be adequate for tumor volume reduction. The compliance of our NeoCT is very good-95% of our patients were able to complete the planned 10-week treatment. The Intergroup study reported only 63% and 55% patients could finish the planned ConCT and AdjCT. All of previous studies using similar design (CCRT + AdjCT) showed similar low compliance rates of ConCT and AdjCT. Although survival analysis showed no statistically significant differences between NeoCT-RT and CCRT in our study, patients who received NeoCT-RT had relatively better DMFFS and OS than those who received CCRT with smaller but not significant P-values (0.1085 and 0.1531).
The major weakness of this study is a retrospective analysis with a relatively small sample size. Of note, the design of combined cisplatin with 5-FU as the concurrent regimen was based on our past experiences 9 . This regimen is different from the standard single agent of cisplatin in most studies. The reported rates on the occurrence of grade 3/4 mucositis during CCRT with tri-weekly high-dose cisplatin were 29% (Intergroup study) 5 , 48.1% (Singapore trial) 10 , 62% (Hong Kong NPC-9901 trial) 9 , and 35.3% (China trial) 26 . Similar rates (31.4% to 48.9%) were observed by changing to a weekly low-dose cisplatin 11, 15, 28 . We obtained a slightly higher grade 3/4 mucositis (55%) when combined cisplatin and 5-FU was used in this study. The acute toxicity discrepancies probably due to different concurrent chemotherapy regimen will limit our results to apply to the patients who receive concurrent chemotherapy with cisplatin alone. In addition, post-RT AdjCT was recommended to patients with high-risk factors that may contribute to the final treatment results. However, no significant differences between CCRT and NeoCT-RT arms in terms of percentage of the patients possessed high-risk factors (P = 0.3853) and those who actually received post-RT adjuvant tegafur-uracil (P = 0.2106). Furthermore, all meta-analyses revealed no survival differences in NPC patients who received or not received post-RT AdjCT. One of the strengths of this study is adequate follow-up time than most of previous reports. We observed that NeoCT-RT have similar long-term survivals, similar severe late events compared with CCRT, but significant reduction of grade 3/4 acute toxicities and emergency room visits. Results of this study suggest that NeoCT-RT could be an attractive alternative option other than CCRT during daily practice.
Methods
Study population. The routine staging workups for newly diagnosed NPC patients in our hospital included a clinical examination of the head and neck region, fiber nasopharyngoscopy with biopsy, magnetic resonance imaging (MRI) with or without computed tomography (CT) scan from the skull base through to the whole neck, chest radiography, whole-body bone scan, abdominal sonography, complete blood count with differentials, platelet count, biochemical profile, EBV antibody titers and plasma EBV DNA concentrations. 18 F-fluorodeoxyglucose positron emission tomography (PET) scan or PET/CT was usually performed for stage III-IV patients in order to confirm that there was no distant metastasis before entry.
The inclusion criteria for this retrospective analysis were 1) previously untreated patients with stage II-IVB diseases according to the 2002 American Joint Committee on Cancer staging system; 2) no history of prior cancer, except for carcinoma in situ of the cervix or non-melanoma cancers of the skin; 3) Karnofsky performance status ≥ 60%; 4) normal liver, renal and bone marrow function; 5) finished curative intensity-modulated radiotherapy (IMRT) with uniform ConCT or NeoCT described below.
Initial definitive treatment.
During the study period, eligible patients were informed the detailed protocols of two different initial definitive chemoradiotherapy (a short 7-week CCRT versus a long course of 10-weekly NeoCT followed by 7-week RT alone). The allocations to different treatment arm were determined by the selection of the patient itself. Physicians in charge started CCRT or NeoCT-RT accordingly within one week after patient decision. This study was approved by the Institutional Review Board of the Taichung Veterans General Hospital, Taiwan, and all procedures were performed according to the Declaration of Helsinki. Written informed consents were obtained from all patients before treatment. Both groups received the same IMRT 70 Gy/35 fractions/7 weeks to the gross tumor volume (primary tumor and positive nodes) plus a 2-4 mm margin. We preferred the use of a hyperfractionated RT with 76. Post-RT adjuvant chemotherapy. During treatment years, our guideline also recommended post-RT AdjCT with oral tegafur-uracil (each capsule contained 100 mg of tegafur and 224 mg of uracil) via 2 capsules, twice daily for 12 months for patients possessing high-risk factors, such as metastatic nodes > 6 cm, supraclavicular node metastasis, skull base destruction/intracranial invasion plus multiple nodes metastasis, or multiple neck nodes metastasis with one node > 4 cm 30 and were initiated approximately 3 months after completion of CCRT/ NeoCT-RT.
Response evaluation and follow-up schedule. Re-staging survey, including MRI or CT scan of the head and neck, chest X-ray, abdominal sonography and whole-body bone scan were performed 2-3 months after completion of the initial CCRT or NeoCT-RT to evaluate tumor response, based on the RECIST criteria 31 . These image studies were repeated once every 6-12 months during the first 2 years, and annually thereafter. PET or PET/CT scan was not part of the follow-up routine, but was usually performed if the above-mentioned examinations were deemed equivocal, or if the physicians in charge wanted to obtain a confirmatory diagnosis and evaluation of the extent of recurrence/metastasis before any salvage treatment.
The frequency of post-RT follow-up occurs every 1-2 months in the first year, every 2-3 months in both the second and third years, every 3-6 months in both the fourth and fifth years, and annually thereafter. Flexible nasopharyngoscopy was performed once per 3-6 months during the patient's follow-up visits.
Statistical analysis. The primary end-points of this study were progression-free survival (PFS) and overall survival (OS). The secondary end-points were the tumor response rates after the initial definitive treatments, acute and late toxicities, nasopharynx failure-free survival (NPFFS), neck failure-free survival (NFFS), and distant metastasis failure-free survival (DMFFS) between the two groups. PFS was defined as being the time from the first date of definitive treatment, to the time of disease progression or death. OS was defined as the date from which the first day of definitive treatment began, until death of any cause or the date of the last follow-up visit. NPFFS, NFFS, and DMFFS were calculated as being from the first date of definitive treatment until the date of the first occurrence of primary, neck or distant relapse, or the date of the last follow-up visit. An intention-to-treat principle was applied for all patients involved in the analysis.
Patient characteristics and other variables were compared as follows: the Student t test was used for continuous variables of the two groups. The Chi-square test was used for category or ordinal variables. The Fisher's exact test SCIeNTIFIC REPORTs | (2018) 8:470 | DOI:10.1038/s41598-017-18713-z was used when a small sample size existed. Survival curves were estimated through the use of the product-limit method. Survival differences between different subgroups were then analyzed using the log-rank test. All of these statistical tests are two-sided and a P value of less than 0.05 is considered statistically significant. Analyses were performed by the use of SAS (Version 8.0; SAS Institute, Inc., Cary, NC).
